Research
The document a trial doctor reads before the first patient
Every investigator in a drug trial is handed one document before the work starts, and signs to say they have read it. Federal regulation lists exactly what is in it, and the list is a fair standard to hold any product page against.
One document, handed over before anything begins
Before a doctor gives an investigational drug to a first participant, they receive a specific written document about it.
It has a plain name in the rules, the investigator brochure, and a defined contents list. It is not a label, not a marketing summary, and not a scientific paper.
It is the honest account of what is known about the compound so far, assembled by the people who want it studied, for the people who will be handing it to patients.
Who gives it, and when
The duty is on the sponsor, and the timing is before rather than during.
Before the investigation begins, a sponsor gives each participating clinical investigator a brochure containing the specified information.
One party is excused, and the reason is structural rather than lenient. A sponsor-investigator, meaning the individual who both initiates and conducts the study, is outside this requirement.
That person already holds everything the brochure would contain, because they assembled it. The rule does not require anyone to formally inform themselves.
The five things inside it
The contents are set out in the filing rules, and there are five.
A brief description of the drug substance and the formulation, including the structural formula if it is known.
A summary of the pharmacological and toxicological effects of the drug in animals and, to the extent known, in humans.
A summary of the pharmacokinetics and biological disposition of the drug in animals and, if known, in humans.
A summary of information relating to safety and effectiveness in humans obtained from prior clinical studies, with reprints of published articles appended where useful.
And a description of possible risks and side effects anticipated on the basis of prior experience with the drug or with related drugs.
The fifth item has a second half
That last element does not stop at listing risks. It also has to describe the precautions or special monitoring to be done as part of the investigational use of the drug.
So the document is not only a warning, it is an instruction. A known risk arrives attached to what should be watched for it.
Read the five together and a pattern appears. Each one has a scope marker: in animals, to the extent known in humans, if known, from prior clinical studies.
The document is written to make the boundary of knowledge visible rather than to smooth it over. That is the feature worth carrying to any other page that describes a compound.
The signature that says it was read
Handing the document over is one duty. Reading it is another, and it is a personal one.
Before an investigator may take part, the sponsor obtains a signed statement from them carrying a list of commitments.
One of those commitments is that the investigator has read and understands the information in the brochure, including the potential risks and side effects of the drug.
That is a named individual attesting, in writing, that they know what is currently known about a compound before they give it to anyone.
It sits in the same signed statement as their commitments to follow the protocol, to obtain consent, and to report adverse experiences.
It is not allowed to go stale
A brochure describing what was known at the start would be worth little by the middle of a program, and the rules treat it as a living document.
As the overall investigation proceeds, the sponsor keeps each participating investigator informed of new observations discovered by or reported to them, particularly with respect to adverse effects and safe use.
How that happens is deliberately open. Periodically revised brochures, reprints or published studies, reports or letters to clinical investigators, or other appropriate means all satisfy it.
Urgent material has its own lane. Important safety information is relayed under the safety reporting rules rather than waiting for the next revision.
Once a year, someone has to account for it
The updating duty could easily be satisfied loosely, so a second rule checks it annually.
The annual progress report must state, where the brochure has been revised, a description of the revision. A copy of the new brochure goes with it.
That turns an open-ended duty into a yearly artifact. Either the document changed and the change is described, or it did not.
It also gives the file a record of how understanding of the compound moved over time, which is a different and more honest thing than a final summary.
Why the document doubles as a measuring stick
The brochure has a second job that makes it more consequential than an information packet.
Inside a study, whether an adverse event counts as unexpected is decided by comparing it to this document rather than to a product label.
That comparison is worked through in a companion article on trial safety reporting, and the mechanics are not repeated here.
The point for present purposes is what it implies about the brochure itself. A document used as the reference for classifying harm has to be complete and current, or the classification is wrong.
What the equivalent looks like outside a trial
Line the five items up against what a person buying a compound online receives, and the gap is specific rather than vague.
A description of the substance and the formulation. A summary of pharmacological and toxicological effects in animals and, so far as known, in humans.
A summary of how the body handles it. A summary of safety and effectiveness from prior human studies. A description of anticipated risks and side effects, with the monitoring that goes with them.
Nothing prevents a seller from publishing that. Where a page is thin, the useful question is which of the five it is thin on, and whether the missing one is knowledge that does not exist or knowledge that was not passed along.
And the signature is worth keeping in mind too. Inside the system, someone puts their name to having read the risks before anyone takes the compound.
Key takeaways
- Each participating investigator receives a brochure about the drug before the investigation begins, from the sponsor.
- Its five required contents cover the substance and formulation, animal and human pharmacology and toxicology, pharmacokinetics, prior human safety and effectiveness, and anticipated risks.
- The risks element also requires the precautions or special monitoring to be carried out during investigational use.
- Every element carries an explicit scope marker, so the boundary of what is known stays visible.
- Investigators sign a statement that they have read and understand the brochure, including potential risks and side effects.
- Sponsors must keep investigators informed of new observations, particularly adverse effects and safe use, with urgent material on the safety reporting channel.
- Any revision must be described in the annual report, with a copy of the new brochure attached.
Frequently asked questions
What is an investigator brochure?
The document a sponsor gives each participating clinical investigator before an investigation begins. Federal regulation specifies five contents. A description of the drug substance and formulation, with the structural formula if known. A summary of pharmacological and toxicological effects in animals and, to the extent known, in humans. A summary of pharmacokinetics and biological disposition. A summary of safety and effectiveness from prior clinical studies. And a description of possible risks and side effects.
Does it say what to watch for, or only what could go wrong?
Both. The risks element also requires a description of precautions or special monitoring to be done as part of the investigational use of the drug. A risk is stated together with what should be monitored because of it, which is what makes the document usable at the bedside rather than only informative.
Does an investigator have to confirm they read it?
Yes, in writing and personally. A sponsor must obtain a signed investigator statement before that person begins. It carries a commitment that the investigator has read and understands the information in the brochure, including the potential risks and side effects of the drug. It sits alongside their commitments to follow the protocol, obtain consent and report adverse experiences.
Is the brochure updated during a study?
It has to be kept current in substance. As the investigation proceeds, the sponsor keeps each participating investigator informed of new observations, particularly regarding adverse effects and safe use. Delivery may be through periodically revised brochures, reprints, published studies, reports or letters, or other appropriate means, and important safety information travels on the separate safety reporting channel.
Who checks that it was actually revised?
The annual report does. Where the brochure has been revised, the sponsor must include a description of the revision and a copy of the new brochure. That converts an ongoing duty into a yearly artifact, and leaves the file with a record of how understanding of the compound changed.
Does every study have one?
Not quite. The requirement falls on a sponsor other than a sponsor-investigator, meaning the individual who both initiates and conducts the investigation. That person is not required to formally inform themselves of material they assembled. Everyone else running a study under a sponsor receives one before beginning.
Sources
Each document below is named as it names itself, with the date printed on that document rather than the day it was read.
- 21 CFR 312.23 — IND content and format, whose paragraph (a)(5) lists the brochure contents — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
- 21 CFR 312.55 — Informing investigators — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
- 21 CFR 312.53 — Selecting investigators and monitors, whose signed statement includes the commitment that the investigator has read and understands the brochure — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
- 21 CFR 312.33 — Annual reports, requiring a description of any brochure revision and a copy of the new brochure — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026